The need for a regen industry voice

On the genealogy of tissue engineering and regenerative medicine

In this article, we identify and discuss a timeline of historical events and scientific breakthroughs that shaped the principles of tissue engineering and regenerative medicine (TERM). We explore the origins of TERM concepts in myths, their application in the ancient era, their resurgence during Enlightenment, and, finally, their systematic codification into an emerging scientific and technological framework in recent past. The development of computational/mathematical approaches in TERM is also briefly discussed.

ISSCR 2009 Industry Panel Session: promoting translation and commercialization

This report presents the recommendations to the ISSCR leadership from the industry panel session at the 2009 annual conference. The seven recommendations address core issues essential for the promotion of stem cell and regenerative medicine translation and commercialization.

Bioreactor-based roadmap for the translation of tissue engineering strategies into clinical products

Despite the compelling clinical need to regenerate damaged tissues/organs, impressive advances in the field of tissue engineering have yet to result in viable engineered tissue products with widespread therapeutic adoption. Although bioreactor systems have been proposed as a key factor in the manufacture of standardized and cost-effective engineered products, this concept appears slow to be embraced and implemented. Here we address scientific, regulatory and commercial challenges intrinsic to the bioreactor-based translation of tissue engineering models into clinical products, proposing a roadmap for the implementation of a new paradigm. The roadmap highlights that bioreactors must be implemented throughout product development, allowing scientific, medical, industrial and regulatory parties to address basic research questions, conduct sound pre-clinical studies and ultimately facilitating effective commercialization of engineered clinical products.